Every 8-K that 4D Molecular Therapeutics, Inc. (FDMT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow FDMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FDMT filings page.
4D Molecular Therapeutics reported Q2 2026 results highlighted by late-stage clinical progress and a strengthened balance sheet. Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, which, together with expected Otsuka collaboration payments, is estimated to fund operations into the second half of 2028. The company also entered a strategic credit facility with Hercules Capital for up to $200 million, drawing $20 million at closing.
Collaboration and license revenue was $3.8 million in Q2 2026, while research and development expenses rose to $68.3 million and general and administrative expenses to $12.5 million. Net loss was $72.9 million, or $1.04 per share. Clinically, enrollment was completed in both 4FRONT-1 and 4FRONT-2 Phase 3 trials of 4D-150 for wet AMD, with topline data expected in 2027, and a Phase 3 DME trial is planned to start in Q3 2026. Two-year PRISM Phase 2b data showed sustained visual outcomes and a 78–87% reduction in treatment burden versus projected aflibercept dosing, with a favorable safety profile.
4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating its product candidate 4D-150 in a broad wet age-related macular degeneration population, based on a data cutoff of May 18, 2026. The disclosure highlights trial and patient cohort overview information, Phase 2b efficacy results through 2 years, and safety data for the selected Phase 3 dose across the overall PRISM Phase 1/2a and 2b clinical trial population of 71 patients.
The company explains that statements about the therapeutic potential, treatment-burden reduction, durability and success of clinical trials for 4D-150 are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties described in its most recent quarterly report filed on May 7, 2026, and the company disclaims any obligation to update forward-looking statements.
4D Molecular Therapeutics, Inc. entered into a new senior secured Loan and Security Agreement with Hercules Capital providing term loans in an aggregate principal amount of up to $200.0 million. The facility matures on June 1, 2031 and is structured in multiple tranches, including a Tranche 1A Loan of $20.0 million drawn at closing, a Tranche 1B Loan of $30.0 million available at the company’s election until June 15, 2027, and additional milestone-based tranches totaling $100.0 million plus a discretionary $50.0 million tranche.
Tranche 1A bears interest at the greater of the prime rate plus 2.00% or 8.75%, while the other tranches bear the greater of the prime rate plus 2.50% or 9.25%, all payable monthly in arrears and capped at 0.75% above the rate in effect on funding. The company must pay a $500,000 Initial Facility Charge and a 1.00% Tranche Facility Charge on advances from Tranche 2 through Tranche 5.
The agreement includes minimum cash covenants tied to outstanding obligations and company market capitalization, a performance covenant triggered after FDA approval of the lead product candidate and borrowings of at least $75.0 million, and events of default that can accelerate all obligations. The loans are secured by substantially all company assets, including intellectual property, and certain future subsidiaries may be required to guarantee and pledge their assets.
4D Molecular Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the record date on April 20, 2026, there were 52,274,735 common shares outstanding, and 44,038,022 shares were represented in person or by proxy at the meeting.
Stockholders elected Class III directors Nancy Miller-Rich, John F. Milligan, Ph.D., and Shawn Cline Tomasello, MBA to serve until the 2029 Annual Meeting or until their successors are elected. Votes for these nominees ranged from 30.5 million to 35.9 million, with additional broker non-votes recorded.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 43,900,362 votes for. In an advisory vote, stockholders approved the compensation of named executive officers, with 36,065,437 votes for and 940,414 against.
4D Molecular Therapeutics reported Q1 2026 results highlighted by advancing its lead eye disease program and maintaining a strong balance sheet. Collaboration and license revenue reached $3.0 million, while research and development expenses rose to $65.0 million as the company executed Phase 3 trials for 4D-150 in wet age-related macular degeneration.
General and administrative expenses were $11.7 million, and net loss was $68.8 million, or $1.01 per share. Cash, cash equivalents and marketable securities totaled $458 million as of March 31, 2026, which the company expects will fund operations into the second half of 2028. The 4FRONT-1 Phase 3 trial completed randomization of 523 patients, with topline data expected in the first half of 2027, and additional PRISM, SPECTRA and DME Phase 3 milestones are planned through 2026–2027.
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.
Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.
4D Molecular Therapeutics reported full year 2025 results and highlighted major partnering and financing activities that support its late-stage gene therapy pipeline. Collaboration and license revenue rose to $85.2 million, mainly from an upfront payment under the Otsuka partnership, while net loss narrowed to $140.1 million from $160.9 million in 2024. Research and development expenses increased to $195.7 million, reflecting advancement of the 4D-150 Phase 3 wet AMD program and other trials. Cash, cash equivalents and marketable securities were $514.0 million as of December 31, 2025, which the company expects will fund its operating plan into the second half of 2028. The company also completed an additional $118 million in equity financings and reported positive interim data and upcoming milestones for 4D-150 in retinal diseases and 4D-710 for cystic fibrosis lung disease.
4D Molecular Therapeutics entered exchange agreements with RA Capital and Biotechnology Value Fund, under which RA Capital exchanged 4,850,000 common shares and BVF exchanged 1,750,000 common shares for pre-funded warrants to acquire the same number of shares.
As of January 23, 2026, the company had 51,007,874 common shares outstanding, excluding 16,935,665 shares issuable upon exercise of pre-funded warrants outstanding on that date. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share, have no expiration until fully exercised, and are subject to beneficial ownership blockers at 4.99% or 9.99%, as specified in each warrant. The warrants were issued without registration in reliance on the Section 3(a)(9) exemption under the Securities Act.
4D Molecular Therapeutics reported a preliminary estimate of approximately $514 million in cash, cash equivalents and marketable securities as of December 31, 2025, noting this figure is unaudited and may change once year-end closing procedures are complete. The company also announced that President and Chief Operating Officer Fariborz Kamal, Ph.D., resigned from those roles on December 31, 2025 to pursue other opportunities, and moved to a part-time position as Chief Technical Advisor, with no disagreements cited regarding operations or strategy.
Effective January 1, 2026, Chief Executive Officer David Kirn, M.D., was also appointed President. In addition, effective January 5, 2026, the Board appointed Glenn Sblendorio as a Class I director and member of the Compensation and Science and Technology Committees, granting him an initial option to purchase 45,000 shares at an exercise price of $7.30 per share and cash retainers consistent with the company’s non-employee director compensation program.
4D Molecular Therapeutics, Inc. (FDMT) appointed Kristian Humer as its new Chief Financial Officer and Principal Financial Officer effective November 17, 2025. Humer brings experience from senior finance roles at Foghorn Therapeutics, Viridian Therapeutics, and Citigroup’s healthcare investment banking group. Under his offer letter, he receives an annual base salary of $520,000, a target annual bonus equal to 40% of base salary, a stock option to purchase 480,000 shares of common stock, and a $100,000 sign-on bonus paid in two installments with multi-year earn-out conditions tied to continued employment. If he is terminated without cause or resigns for good reason, he is eligible for severance benefits, including salary continuation and COBRA premium reimbursement, with enhanced benefits and full vesting acceleration of equity awards if such a termination occurs within 12 months after a change in control.
4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025. The company furnished a press release titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1. The filing indicates that the release also covers recent operational developments and outlines milestones the company expects in the future.
4D Molecular Therapeutics (FDMT) completed an underwritten equity offering, issuing 8,385,809 shares of common stock at $10.51 per share and pre-funded warrants for 1,128,949 shares at $10.5099 per warrant. The company reported net proceeds of approximately $93.3 million after underwriting discounts and expenses, and the transaction closed on November 7, 2025.
Underwriters purchased the shares at $9.8794 and the pre-funded warrants at $9.8793. The offering was conducted via a prospectus supplement under FDMT’s Form S-3 (effective August 15, 2023). Directors and executive officers agreed to a lock-up through January 6, 2026, subject to customary exceptions.
4D Molecular Therapeutics (FDMT) reported a preliminary cash, cash equivalents and marketable securities balance of $372.2 million as of September 30, 2025. The company also announced positive interim 1.5–3.5-year data from its Phase 1/2 PRISM trial of 4D-150 in wet age-related macular degeneration.
Across cohorts, patients showed sustained reductions in supplemental anti-VEGF injections after 4D-150. In the Phase 2b recently diagnosed subgroup (Phase 3 comparable), mean supplemental injections were reduced 94% through year 1 and 92% through year 1.5. The broader Phase 2b cohort showed 83% through year 1 and 82% through year 1.5, while the Phase 1/2a severe, recalcitrant cohort showed 83% through year 1 and 79% through year 2. By 6‑month segments, the Phase 2b recently diagnosed subgroup recorded mean injections per patient of 0.1 (months 0–6), 0.2 (6–12), and 0.4 (12–18).
4D Molecular Therapeutics (FDMT) announced a collaboration and license agreement with Otsuka Pharmaceutical granting Otsuka exclusive rights to develop and commercialize 4D-150 for ophthalmological diseases in Japan, China, Australia and other APAC markets. The Company will continue to lead all Phase 3 clinical activity globally, while Otsuka will lead regulatory and commercialization in its territories.
Financial terms include an $85 million upfront cash payment, expected cost sharing of at least $50 million over the next three years for global development, eligibility for up to $335.5 million in potential regulatory and commercial milestones, and tiered double-digit royalties on net sales in Otsuka’s territories. 4DMT retains full rights outside APAC, including the U.S., Latin America and Europe.
Operationally, APAC sites in 4FRONT-2 (global Phase 3 in wet AMD) are expected to open by year-end, with Japan sites expected to open in January 2026. Enrollment in 4FRONT-1 continues to exceed initial expectations, with over 200 patients randomized as of October 30, 2025. The agreement includes customary governance via a joint steering committee and standard termination and indemnity provisions.
4D Molecular Therapeutics reported two corporate governance updates. The Board appointed Ashoo Gupta, age 49, as the company’s Principal Financial Officer and Principal Accounting Officer, effective September 30, 2025. He has been Vice President, Finance & Controller since June 2024 and previously held senior finance and controller roles at Kyverna Therapeutics and Myovant Sciences. He will enter into the company’s standard indemnification agreement.
The Board also approved amended and restated bylaws on September 30, 2025. The changes include updates to the advance notice procedures for stockholder proposals of business and for the nomination of directors at meetings. The full text of the amended and restated bylaws is filed as an exhibit and incorporated by reference.
4D Molecular Therapeutics announced that it furnished a press release reporting its financial results for the three months ended June 30, 2025. The Form 8-K references a press release titled "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" as Exhibit 99.1 and includes an interactive data file as Exhibit 104. The company’s common stock trades on the Nasdaq Global Select Market under the ticker FDMT. The filing itself does not include numerical financial details in the text provided here; investors must consult Exhibit 99.1 for the full results and operational highlights.
On June 17, 2025, 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) held its 2025 virtual Annual Meeting of Stockholders. Of the 46.3 million outstanding shares, 38.5 million (≈83%) were represented in person or by proxy.
- Director elections (Proposal 1): All three Class II nominees were re-elected to serve until the 2028 AGM. Support ranged from 84.5% (Dr. Charles P. Theuer) to 98.9% (Susannah Gray).
- Auditor ratification (Proposal 2): Shareholders overwhelmingly confirmed PricewaterhouseCoopers LLP for FY 2025 (≈99.8% in favor).
- Say-on-pay (Proposal 3): 98.7% of votes cast approved FY 2024 executive compensation on an advisory basis.
- Say-on-pay frequency (Proposal 4): A majority (≈99%) selected one-year intervals for future advisory votes; the board will follow this cadence.
No other business or material transactions were reported. The results signal continued shareholder endorsement of the company’s leadership, compensation practices, and external auditor.